Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.78) by 14.1 percent. This is a 11.84 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $18.45 million which beat the analyst consensus estimate of $12.71 million by 45.18 percent. This is a 11.26 percent increase over sales of $16.59 million the same period last year.